Beijing, Aug 28, 2026 — China’s National Medical Products Administration (NMPA) suspended sales and use of two batches of Pierre Fabre Medicament’s Encorafenib capsules after a remote inspection found the French drugmaker used an unapproved active pharmaceutical ingredient process change in production and released the product to the Chinese market despite serious quality management deviations.

Regulatory Snapshot

Attribute	Detail
Issuer	National Medical Products Administration (NMPA)
Announcement	2026 No. 81
Target company	Pierre Fabre Medicament (France)
Product	Encorafenib Capsules (国药准字HJ20250082)
Affected batches	5G2T3, 5G2T4
Manufacturing sites	14 Schoolhouse Road, Somerset, NJ, USA; Site Progipharm, rue du Lycée, 45500 Gien, France
Inspection type	Remote inspection
Violation	Unapproved API process change; serious GMP deviation in change control and release review
Legal basis	Drug Administration Law, Article 99; Provisions for Overseas Inspections of Drugs and Medical Devices, Article 30
Effective date	Immediate

Violation Details

The NMPA said its remote review determined that Pierre Fabre had implemented a significant manufacturing process change for the Encorafenib API without obtaining regulatory approval. The company nonetheless used the modified API to produce batches 5G2T3 and 5G2T4, subsequently releasing them for sale in China. Regulators found that the firm’s change-control procedures and batch-release review processes seriously deviated from China’s Good Manufacturing Practice standards (2010 revision) and associated annexes, failing to meet statutory quality system requirements.

Market Impact Analysis

The suspension immediately blocks distribution of the two Encorafenib batches in China, where the BRAF inhibitor is used in oncology protocols, notably for metastatic colorectal cancer with BRAF V600E mutations. For Pierre Fabre, the enforcement action threatens its commercial standing in a key emerging market and raises questions about global change-control governance, given that the API modification appears to have been implemented across manufacturing sites in both the United States and France.

The case marks a significant use of remote inspection authority under Article 99 of the Drug Administration Law, signaling that the NMPA is prepared to invoke market suspension powers based on procedural and quality-system lapses without waiting for confirmed clinical adverse events. The dual-site manufacturing footprint—spanning New Jersey and Gien—suggests the unapproved process change may have broader implications beyond the two flagged batches, potentially triggering portfolio-wide scrutiny.

Forward-Looking Statement

Industry analysts expect Pierre Fabre to face a lengthy remediation process requiring submission of a formal API process change application, completion of supplementary validation studies, and a re-inspection before the suspension can be lifted. The NMPA’s reliance on remote inspection technology to detect the deviation underscores the growing effectiveness of China’s overseas oversight regime, potentially encouraging similar actions against other multinational drugmakers with manufacturing discrepancies. Oncology treatment centers in China may need to source alternative BRAF inhibitor therapies or draw from unaffected inventory batches while the two suspended lots are quarantined and recalled. The case is likely to prompt multinational pharmaceutical companies to audit their global change-control matrices against Chinese GMP requirements more rigorously, particularly for products manufactured across multiple international sites.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260826174000158.html

Xiamen, Aug 26, 2026 — China’s deputy drug regulator Lei Ping opened the 16th International Conference on Medical Device Supervision and Administration, pledging to deepen review reforms, tighten full-lifecycle quality controls, and align the sector with the nation’s 15th Five-Year Plan innovation targets as Beijing seeks to advance its high-end medical device industry.

Conference Snapshot

Attribute	Detail
Event	16th International Conference on Medical Device Supervision and Administration in China
Location	Xiamen, Fujian Province
Date	Aug 26, 2026
Key officials	Lei Ping, Deputy Commissioner, National Medical Products Administration (NMPA); Wu Bin, Vice Governor of Fujian Province
Attendees	Domestic and international regulators, international organizations, industry associations, academic institutions, medical device enterprises

Regulatory Priorities

Lei outlined the NMPA’s strategic focus across four pillars:

• Review reform — Sustained deepening of medical device evaluation and approval system reforms to accelerate market access.
• Innovation support — Full backing for high-end medical device research, development, and commercialization.
• Lifecycle oversight — Strengthened quality supervision across the entire product lifecycle.
• Global engagement — Expanded international regulatory cooperation and technical exchange.

15th Five-Year Plan Alignment

Lei signaled that the NMPA will anchor its next-phase agenda to the 15th Five-Year Plan development goals, emphasizing that high-efficiency regulation will serve as the foundation for high-level safety, industrial innovation, and high-quality sector growth. The framework aims to translate regulatory capacity into improved public health outcomes.

Bilateral and Industry Engagement

During the conference, Lei held a bilateral meeting with Sulyvong Chokinnaly, Deputy Director-General of the Lao Food and Drug Administration, and participated in roundtable discussions with domestic and international medical device enterprise representatives. The sessions focused on regulatory convergence, market access, and cross-border quality assurance cooperation.

Market Impact Analysis

The Xiamen summit underscores Beijing’s dual-track strategy for the medical device sector: accelerating innovation pathways for domestic high-end manufacturers while tightening quality guardrails through full-lifecycle oversight. Lei’s emphasis on 15th Five-Year Plan alignment suggests forthcoming regulatory reforms will prioritize breakthrough technologies—such as implantable devices, AI-enabled diagnostics, and advanced imaging systems—through streamlined approval channels.

For multinational device makers, the expanded international cooperation agenda signals potential convergence opportunities with China’s regulatory standards, though full-lifecycle oversight commitments imply intensified post-market surveillance obligations. The bilateral engagement with Lao regulators also highlights China’s ambition to export regulatory frameworks and capacity-building support to Southeast Asian markets, potentially smoothing market entry for Chinese device manufacturers in the Mekong region.

Forward-Looking Statement

Industry analysts expect the NMPA to roll out detailed 15th Five-Year Plan implementation guidelines for medical device supervision by late 2026 or early 2027, likely including dedicated fast-track pathways for breakthrough devices and enhanced digital surveillance infrastructure for post-market adverse event monitoring. The Xiamen conference’s focus on high-end innovation suggests regulatory capital will flow toward cardiovascular, neurological, and robotic surgery device segments, where China is seeking to reduce import dependence. Companies with pipeline candidates in these categories should prepare for accelerated review timelines coupled with stricter clinical evidence requirements.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/ylqxhyxx/20260826181534121.html